ASCO® 2026 Highlights: Presenter Vignette – James Smithy

Dr. James Smithy

James Smithy

MD, MHS

Memorial Sloan Kettering Cancer Center

9519

A phase 2 trial of IO102-IO103 and nivolumab-relatlimab in previously untreated, unresectable melanoma.